Shares of Medpace Holdings Inc. (MEDP) are up over 40% in premarket trading Tuesday, following strong financial results for the second quarter ended June 30, 2025, and rosy outlook for the year.
The company is a global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries.
Q2 Scorecard
On a GAAP basis, net income for the second quarter of 2025 increased to $90.3 million, or $3.10 per share, from $88.4 million, or $2.75 per share, in the year-ago period.
Revenue for Q2, 2025 jumped 14.2% to $603.3 million from $528.1 million in Q2, 2024.
Cash and cash equivalents were $46.3 million on June 30, 2025.
Upbeat Guidance
Medpace has raised its full-year 2025 outlook for the second time, reflecting sustained growth and improving fundamentals.
Now, the company expects 2025 to range between $2.420 billion and $2.520 billion, representing year-over-year growth of 14.7% to 19.5% compared to 2024 revenue of $2.109 billion.
GAAP net income for full year 2025 is now expected to be in the range of $405.0 million to $428.0 million. On a per share basis, net income is projected to be in the range of $13.76 to $14.53. The company's GAAP net income for the full year 2024 was $404.4 million, or $12.63 per share.
MEDP has traded in a range of $250.05 to $397.06 in the last 1 year. When we alerted readers to MEDP on Aug.15, 2024, it was trading at $388.
The stock closed yesterday's trading at $308.88, down 0.96%. In premarket trading today, MEDP is up nearly 43% at $441.56.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.